Thera-SAbDab

FRUNEVETMAB

>   Structural Summary
TherapeuticFrunevetmab
TargetNGFB
Heavy ChainQVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA
Light ChainDIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFeline Whole mAb
IsotypeG1
Highest Clinical Trial (June '19)Unknown
Estimated Status (June '19)Active
Recorded Developmental TechnologyPETization Technology
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedNexvet
Conditions Approvedna
Conditions ActiveFeline osteoarthritis
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]